http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013225641-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8aa108cb932ae530bc67b934dbe904fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d1fcf29b928169b4cc3efbb66e37d6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf6b8771920ad938bd1b0e2c690190d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a3a814c804e1fd9656cbf47d69b6f7f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-81 |
| filingDate | 2010-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e51c4caad16a13e2a95a6f48c95cbb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5b46ca8be263677483dfa5c74ac89f0 |
| publicationDate | 2013-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2013225641-A1 |
| titleOfInvention | Anticancer compounds and preparation methods thereof |
| abstract | Two new compounds with anticancer effects of N-[4-chloro-3-(trifluoromethyl)phenyl]-[4-(N-methyl-formamide)(4-pyridyloxy)phenyl]-thiourea and N-[4-chloro-3-(trifluoromethyl)phenyl]-[4-(N-methyl-formamide)(4-pyridylthio)phenyl]-thiourea, and salts thereof are disclosed. Preparation methods of the two new compounds and pharmaceutical compositions containing the new compounds are further disclosed. Experimental studies show that the two new compounds can effectively inhibit the activity of Raf and VEGFR protein kinase, widely inhibit growth of various types of human tumor cell lines and further induce apoptosis of tumor cells. Human tumor heterograft model investigation proves that the two new compounds are effective antineoplastic agents, and can sharply inhibit growth of human liver cancer cells, lung cancer cells and intestinal cancer cells in vivo. Furthermore, the anticancer effects of the compounds are much better than that of Sorafenib. |
| priorityDate | 2010-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 175.